Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

PHASE3CompletedINTERVENTIONAL
Enrollment

663

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2017

Study Completion Date

May 31, 2018

Conditions
Hematoma
Interventions
DRUG

Dabigatran

NOAC

DRUG

Rivaroxaban

NOAC

DRUG

Apixaban

NOAC

Trial Locations (15)

22100

Galilee Medical Center, Nahariya

T2N 2T9

Foothills Medical Centre, Calgary

T5H 3V9

University of Alberta-ECAT Group, Edmonton

V8T 1Z4

Victoria Cardiac Arrhythmia Trials Inc., Victoria

L8L 2X2

Hamilton Health Sciences General Campus, Hamilton

L3Y 2P9

Southlake Regional Health Centre, Newmarket

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

M1E 4B9

Rouge Valley Health System-Centenary Campus, Toronto

M3M 0B2

Humber River Hospital, Toronto

H1T 1C8

Montreal Heart Institute, Montreal

H2W 1T8

Centre Hospitalier de l'Universite de Montreal (CHUM), Hotel Dieu, Montreal

H3G 1A4

McGill University Health Centre/Montreal General Hospital, Montreal

H4J 1C5

Hopital Sacre-Coeur, Montreal

JiH 5N4

Centre Hospitalier Universitaire de Sherbrooke-Hopital Fleurimont, Sherbrooke

G1V 4G5

Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Heart and Stroke Foundation of Canada

OTHER

collaborator

Bayer

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Ottawa Heart Institute Research Corporation

OTHER

NCT01675076 - Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events | Biotech Hunter | Biotech Hunter